By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Two investment firms today separately raised estimates for Complete Genomics and Danaher.

Oppenheimer raised its share price target for Complete Genomics to $18.50, while Jefferies increased its 2011 EPS for Danaher to $2.70 and upped its share price target for the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.